0001209191-22-053659.txt : 20221014
0001209191-22-053659.hdr.sgml : 20221014
20221014160856
ACCESSION NUMBER: 0001209191-22-053659
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221012
FILED AS OF DATE: 20221014
DATE AS OF CHANGE: 20221014
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aftab Blake
CENTRAL INDEX KEY: 0001886986
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 221311451
MAIL ADDRESS:
STREET 1: C/O ADICET BIO, INC.
STREET 2: 200 CLARENDON STREET, FLOOR 6
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-10-12
0
0001720580
Adicet Bio, Inc.
ACET
0001886986
Aftab Blake
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
0
1
0
0
Chief Scientific Officer
Common Stock
2022-10-12
4
M
0
3388
7.38
A
52822
D
Common Stock
2022-10-12
4
S
0
1646
15.40
D
51176
D
Common Stock
2022-10-13
4
F
0
7933
15.92
D
43243
D
Stock Option (Right to Buy)
7.38
2022-10-12
4
M
0
3388
0.00
D
2031-10-11
Common Stock
3388
56612
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
A total of 60,000 shares subject to an employee stock option were granted to the Reporting Person on October 12, 2021. 25% of the shares subject to the stock option vested and became exercisable on October 12, 2022, with the remainder vesting in equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continued service with the Issuer.
/s/ Nick Harvey, Attorney-in-Fact
2022-10-14